Welcome to our dedicated page for BCYP news (Ticker: BCYP), a resource for investors and traders seeking the latest updates and insights on BCYP stock.
This page contains historical news coverage for Big Cypress Acquisition Corp (BCYP), which operated as a Special Purpose Acquisition Company focused on the life sciences sector. Big Cypress completed its business combination with SAB Biotherapeutics in October 2021, and the combined company now trades on NASDAQ as SAB Biotherapeutics (SABS). This archive provides context on the SPAC's formation, merger process, and the events leading to its successful business combination.
Historical news for Big Cypress Acquisition Corp primarily covered the company's IPO in January 2021, the announcement of its proposed merger with SAB Biotherapeutics in June 2021, and the stockholder approval process leading to the October 2021 merger completion. SPAC-related news typically includes coverage of management team backgrounds, target company evaluations, merger terms and valuations, redemption rates, and regulatory filings with the Securities and Exchange Commission.
For investors researching the current operational entity, news coverage of SAB Biotherapeutics is available under the SABS ticker symbol. SAB Biotherapeutics news focuses on clinical trial updates, FDA regulatory interactions, pipeline development progress, and financing activities. Understanding the historical SPAC merger process documented in this archive provides useful context for evaluating how SAB Biotherapeutics transitioned to public markets and the strategic rationale behind the business combination.
Big Cypress Acquisition Corp. (NASDAQ: BCYP) announced that its stockholders approved the business combination with SAB Biotherapeutics, Inc. on October 20, 2021. Approximately 98.3% of votes cast favored the merger, representing 78.6% of outstanding shares. The combination is expected to close on October 22, 2021, with trading under the new ticker symbols 'SABS' and 'SABSW' starting on October 25, 2021. The merger aims to enhance SAB's development of novel immunotherapy treatments, supported by recent clinical advancements, government funding, and infrastructure growth.
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company, will host a virtual R&D Day on October 13, 2021, at 10:00 a.m. ET. The event aims to showcase its DiversitAb™ platform and various clinical programs. Notable speakers include Arturo Casadevall from Johns Hopkins and Michael Haller from the University of Florida. Additionally, SAB announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), expected to finalize in Q4 2021. For more details, visit www.sabbiotherapeutics.com.
SAB Biotherapeutics announced the dosing of the first patient with SAB-185 in the Phase 3 ACTIV-2 trial for non-hospitalized patients with mild to moderate COVID-19. This polyclonal antibody therapeutic has shown potential in neutralizing SARS-CoV-2 variants.
The Phase 3 trial, assessing SAB-185 against active controls, aims to enroll approximately 1,200 participants. The trial's primary endpoint includes safety and non-inferiority for preventing hospitalization or death through day 28.
SAB Biotherapeutics has appointed Russell Beyer as chief financial officer, effective September 20, 2021. With over 25 years of experience in financial operations at major pharmaceutical companies, Beyer aims to enhance SAB's financial growth. The company is advancing its candidate, SAB-185, into a Phase 3 trial, as part of a broader pipeline targeting various diseases. This leadership change coincides with SAB's planned merger with Big Cypress Acquisition Corp, expected to close in the fourth quarter of 2021, potentially strengthening SAB's financial position.
SAB Biotherapeutics announced that its immunotherapy candidate SAB-185 has advanced to Phase 3 of the ACTIV-2 trial, after meeting pre-defined efficacy goals during a Phase 2 interim analysis. This decision was recommended by an independent Data Safety Monitoring Board, based on positive evidence from safety and efficacy studies.
The Phase 3 trial aims to analyze the clinical safety and efficacy of SAB-185 for treating non-hospitalized patients with mild to moderate COVID-19, with approximately 1,200 participants planned.
Big Cypress Acquisition Corp (NASDAQ: BCYP) has announced a Special Meeting on October 20, 2021, for stockholders to vote on a proposed business combination with SAB Biotherapeutics, a clinical-stage biopharmaceutical company focusing on innovative immunotherapies. The SEC has declared effective Big Cypress' Registration Statement to facilitate the transaction. If approved, SAB will become a public entity under the name SAB Biotherapeutics, Inc., with trading set to commence on Nasdaq under the symbols 'DIVR' and 'DIVRW.'
SAB Biotherapeutics received an additional
SAB Biotherapeutics has completed enrollment in its Phase 2a clinical trial for SAB-176, aimed at evaluating the safety and efficacy of this novel anti-influenza immunotherapy. The trial involves 60 healthy adults challenged with a pandemic influenza strain, with expected topline data in 4Q2021. The company also announced a planned merger with Big Cypress Acquisition Corp. (NASDAQ: BCYP), expected to close in Q4 2021. SAB-176 is designed to offer broad protection against influenza A and B strains, potentially improving treatment efficacy for high-risk populations.
SAB Biotherapeutics has announced that its co-founder, Eddie J. Sullivan, PhD, will present at two virtual investor conferences in September. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13 to December 12, featuring pre-recorded presentations. The second is the Baird Global Healthcare Conference on September 14, with a fireside chat format. Additionally, SAB plans to merge with Big Cypress Acquisition Corp. (NASDAQ: BCYP) in Q4 2021, enhancing its clinical-stage biopharmaceutical initiatives.
SAB Biotherapeutics announced positive results for SAB-185, its therapeutic candidate against COVID-19 that effectively neutralizes multiple variants, including Delta and Lambda. The findings, published in bioRxiv, support SAB-185's potential as a treatment amidst rising global infections. Currently in a Phase 2/3 trial for non-hospitalized patients, SAB-185 has shown superior potency compared to human-derived antibodies. This research was conducted with FDA collaboration, enhancing confidence in its efficacy. The planned merger with Big Cypress Acquisition Corp (BCYP) is set to close in Q4 2021, further advancing SAB's clinical objectives.
